Journal of Oncology

Journal of Oncology / 2010 / Article
Special Issue

Epithelial Ovarian Cancer: Focus on Targeted Therapy

View this Special Issue

Editorial | Open Access

Volume 2010 |Article ID 171425 |

M. Markman, Jalid Sehouli, Charles F. Levenback, Dennis S. Chi, "Epithelial Ovarian Cancer: Focus on Targeted Therapy", Journal of Oncology, vol. 2010, Article ID 171425, 1 page, 2010.

Epithelial Ovarian Cancer: Focus on Targeted Therapy

Received31 Dec 2010
Accepted31 Dec 2010
Published05 Jul 2011

Over the past five decades ovarian cancer has been of considerable interest to clinical cancer investigators due to the fact that it is among the most chemosensitive of all solid tumors [1]. Unfortunately, despite the advances in the chemotherapeutic management of this malignancy, the large majority of patients ultimately recur, progress, and ultimately die as a direct result of complications of the disease process. Thus, there is a critical need to find novel agents that may favorably impact the natural history of ovarian cancer.

In recent years there has been a particular focus in the cancer research community to discover and subsequently develop clinically active drugs that are capable of specifically targeting biological pathways relevant in a particular tumor type (e.g., ovarian cancer) and even within a specific patient with that type of cancer (so-called, “personalized medicine”). Research in this arena in ovarian cancer remains in its early stages although a number of quite exciting developments have recently been reported in the peer-reviewed medical literature that suggest the realistic potential that this novel general class of drugs will soon become important components of “standard-of-care” in the management of this difficult malignancy.

In this special issue, investigators from around the world have contributed to this literature by summarizing a number of important developments. In the papers of this special issue, an initial discussion of the role of surgical cytoreduction in the malignancy is followed by an overview of the management of recurrent ovarian cancer and the relevance of molecular abnormalities in specific ovarian cancer subtypes.

This is followed by several excellent and comprehensive overviews of the possible roles of targeted therapy in ovarian cancer, the potential impact of antiangiogenic drugs, epidermal growth factor and PARP inhibitors, disruption of insulin and glucose pathways, and novel treatments affecting histone deacetylase and metastatic colonization, as well as an innovative approach to immunotherapy in the malignancy.

The peer-reviewed papers in this special issue provide important insight into both the current and future management of epithelial ovarian cancer.

M. Markman
Jalid Sehouli
Charles F. Levenback
Dennis S. Chi


  1. B. T. Hennessy, R. L. Coleman, and M. Markman, “Ovarian cancer,” The Lancet, vol. 374, pp. 1371–1382, 2009. View at: Publisher Site | Google Scholar

Copyright © 2010 M. Markman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

More related articles

 PDF Download Citation Citation
 Download other formatsMore
 Order printed copiesOrder

Related articles

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.